LP

LB Pharmaceuticals Inc Common Stock

LBRX·NASDAQ

$27.95

+3.4%
HealthcareBiotechnology

Clinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.

At a Glance

Live Snapshot
Market Cap$801.51M
EPS-1.0000
P/E Ratio-27.95
Earnings Date06/25/2026

lbrx

Short Term Investments

Last Annual Value

45.04M

3-Year CAGR

%

5-Year CAGR

%

10-Year CAGR

%

LP

LB Pharmaceuticals Inc Common Stock Competitors Analysis of Short Term Investments

LBRX · NASDAQ
CompanyShort Term Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
45.04M
16.7%N/AN/A 
84.73M
-22.9%N/AN/A
ANNX logo
Annexon, Inc.
NASDAQ:ANNX
76.29M
30.2%-14.6%N/A
0.00
N/AN/AN/A
HUMA logo
Humacyte, Inc.
NASDAQ:HUMA
0.00
N/AN/AN/A
155.16M
89.2%N/AN/A
187.04M
-22.4%-10.2%N/A
372.69M
-5.2%4.9%N/A
0.00
N/AN/AN/A
111.37M
-29.5%-6.5%1.4%
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
53.33M
N/A0.9%N/A
LP

LB Pharmaceuticals Inc Common Stock Fair Value Envelope

LBRX · NASDAQ

Our analysis suggests that LBRX has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $27.95, this represents a potential HIDDEN relative to our calculated worth for LB Pharmaceuticals Inc Common Stock.

Intrinsic Value
Current Price: $27.95